The current shift of therapy of chronic lymphocytic leukemia (CLL) towards novel targeted agents mandates the identification of molecular predictors to optimize treatment choices. Objective: We aimed at refining the genetic-based stratification of FCR (fludarabine, cyclophosphamide, rituximab) treated CLL patients by integrating the CLL mutational profile in a prognostic model comprising also IGHV mutation status and FISH cytogenetics. Methods: Tumor genomic DNA of 162 untreated CLL was analysed with next-generation-sequencing (NGS) to identify clonal mutations (variant allele frequency >10%) of CLL cancer driver genes (n¼23). The primary outcome was progression free survival (PFS). Medical statistics was performed using SPSS Statistics 24.0 and R statistical package 3.3.2. Results: Among patients categorized as low-risk by IGHV and FISH status, mutations of genes associated with poor prognosis were virtually absent. Among patients categorized as intermediate-risk by IGHV and FISH status, multivariate analysis showed that mutations of BIRC3 (HR: 6.264; 95% CI 2.289-17.145; p<0.001) and BRAF (HR: 4.898; 95% CI: 1.493-16.071; p¼0.009) harbor independent association with an increased risk of progression. Consistently, intermediate-risk patients according to IGHV and FISH were further stratified by recursive partitioning in two groups represented by those harboring BIRC3 or BRAF mutations, and those wild type for both these genes. This information helped refining our previous stratification model of FCR-treated patients based on CLL molecular features. Two high-risk groups emerged sharing a similarly poor PFS, namely i) TP53 mutated and/or deleted CLL (median PFS 2.1 years), and ii) BIRC3 or BRAF mutated CLL (median PFS 0.3 years), representing 4.9% of FCR-treated patients. Conversely, IGHV unmutated patients lacking alterations of TP53, BIRC3 and BRAF lesions had an intermediate outcome (median PFS 5.3 years). Patients with mutated IGHV genes, and lacking TP53, BIRC3, BRAF and del11q lesions had an excellent outcome (median PFS not reached, 50.0% being progression-free at 10 years). Conclusions: BIRC3 and BRAF mutations identify a very poor prognostic subgroup with wild type TP53 but failing FCR as those harboring TP53 disruption. If validated, mutations of BIRC3 and BRAF might be used as molecular predictors to select high-risk patients for novel therapeutic approaches.
Keywords: chronic lymphocytic leukemia, FCR, immunochemotherapy, molecular predictors, precision medicine Context: The current shift of therapy of chronic lymphocytic leukemia (CLL) towards novel targeted agents mandates the identification of molecular predictors to optimize treatment choices. Objective: We aimed at refining the genetic-based stratification of FCR (fludarabine, cyclophosphamide, rituximab) treated CLL patients by integrating the CLL mutational profile in a prognostic model comprising also IGHV mutation status and FISH cytogenetics. Methods: Tumor genomic DNA of 162 untreated CLL was analysed with next-generation-sequencing (NGS) to identify clonal mutations (variant allele frequency >10%) of CLL cancer driver genes (n¼23). The primary outcome was progression free survival (PFS). Medical statistics was performed using SPSS Statistics 24.0 and R statistical package 3. Keywords: CLL, lenalidomide, consolidation Context: Eradication of residual disease is an important endpoint in patients with chronic lymphocytic leukemia (CLL), as it prolongs remission duration after chemoimmunotherapy. Objective: To determine whether consolidation treatment with lenalidomide can produce a response improvement in patients with CLL after completing frontline or salvage chemoimmunotherapy Design: This is a phase 2, single-arm, open-label, single-center study; patients received consolidation with lenalidomide for up to 12 months and median follow-up was f 47 months (range, 7-94 months) Setting: The study was entirely conducted at MD Anderson Cancer Center, Houston, TX Patients or Other Participants: We recruited patients followed at the University of Texas M.D. Anderson Cancer Center who had CLL and either partial remission (PR) or complete remission (CR) with positive minimal residual disease (MRD) after completing front-line or salvage chemoimmunotherapy. Interventions: Oral lenalidomide was given at a starting dose of 10 mg daily for up to 12 months Main Outcomes Measures: The primary endpoint was response improvement (RI), and response was assessed at 4 and 12 months. Results: Thirty-two patients were Abstracts S12 -Clinical Lymphoma, Myeloma & Leukemia October 2017 enrolled in this study. Baseline characteristics are shown in the Table. Five (33%) patients discontinued treatment because of toxicity; 3 of them (9%) had treatment interrupted after 2, 7, and 20 days of therapy and were considered evaluable for toxicity but not for response or PFS.
After 12 months of consolidation therapy, 45% of patients had a RI. Four of the 8 patients who entered consolidation therapy with nPR improved to CR (2 negative for MRD and 2 with positive MRD). Seven of the 15 patients with PR improved to CR (1 negative for MRD and 6 with positive MRD), and 2 of the patients with PR improved to nPR.
The median progression-free survival (PFS) was 30 months. A trend for longer PFS was observed among patients receiving consolidation therapy with lenalidomide after frontline treatment as compared to patients receiving it after salvage therapy (43 vs 29 months, p¼0.08). The most common grade 3-4 treatment-related toxic effects consisted of neutropenia, infections, thrombocytopenia, and pulmonary embolism (observed in 55%, 16%, 6%, and 3% of patients, respectively). Conclusions: In our experience, consolidation therapy with lenalidomide is well tolerated and can improve response to chemoimmunotherapy in patients with CLL. Large randomized studies exploring the efficacy of lenalidomide as a consolidation strategy after front-line and second-line treatment of CLL are ongoing.
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Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
Nitin Jain,Keywords: CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV Context: Chemotherapy has remained the standard treatment for young patients (pts) with CLL. The role of chemotherapy in the era of novel therapies is evolving. Objective: To determine CR rate with minimal rediual disease (MRD) 
